Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2021 Mar 15;14(4):427–437. doi: 10.1080/17512433.2021.1900726

Table 1:

Pharmacokinetic Properties of elagolix in Healthy Subjects

Absorption
Tmax (h) 1.5(1.0 – 4.0)
Effect of Food
High-fat meal (826kcal, 52% fat, relative to fasting) AUC: ↓25%, Cmax: ↓36%
Distribution
% Bound to human plasma proteins 80
Blood-to-plasma ratio 0.6
Metabolism CYP3A (major)Minor pathways include: CYP2D6, CYP2C8, and uridine glucuronosyl transferases (UGTs)
Elimination
Major route of elimination Hepatic metabolism
Terminal phase elimination half-life (t1/2) (h) 5.9± 2.1
% of dose excreted in urine <3
% of dose excreted in feces 90